|
Tabla 2: Antropometría, perfil bioquímico y alteraciones cardiometabólicas de los pacientes durante el seguimiento (N = 40). |
||||
|
Variables |
Basal (2019) |
6 meses (2020) |
12 meses (2020) |
18 meses (2021-2022) |
|
Mediana [mínimo-máximo] |
||||
|
Antropometría, perfil bioquímico y puntaje del riesgo cardiovascular |
||||
|
Score Z del IMC |
2.06 [1.23-2.99] |
2.06 [1.1-3.8] |
2.10 [1.02-2.85] |
2.05 [0.84-2.99] |
|
Presión arterial sistémica, mmHg |
||||
|
Sistólica |
120 [90-140] |
115 [90-140] |
120 [90-135] |
120 [80-140] |
|
Diastólica |
70 [50-90] |
62.5 [55-85] |
68 [52-98] |
70 [60-100] |
|
Glucosa, mg/dL |
95 [82-159] |
91.8 [77.6-118.0] |
94.2 [87.0-118.6] |
87.6 [71.1-108.0]* |
|
Colesterol total, mg/dL |
165 [110-289] |
156.2 [80.0-252.0] |
171.4 [116.3-268.0] |
168.5 [111.0-294.0]* |
|
LDLc, mg/dL |
72.3 [38.8-116.4] |
78.6 [53.0-141.2] |
88.5 [50.9-133.0] |
91.6 [45.3-128.9]* |
|
HDLc, mg/dL |
36.0 [18.7-58.0] |
35.9 [24.6-74.0] |
32.8 [22.8-69.3] |
32.7 [21.0-60.0] |
|
Triglicéridos, mg/dL |
168.1 [72.0-381.0] |
180.1 [64.0-777.9] |
188.8 [63.0-410.3] |
188.9 [92.0-434.0] |
|
Índice de Alustiza |
7 [3-13] |
6 [4-10] |
7 [4-11] |
7 [3-14]* |
|
Factores cardiometabólicos, n (%) |
||||
|
Hiperglucemia |
7 (17.5) |
3 (7.5) |
3 (7.5) |
3 (7.5) |
|
Hipertrigliceridemia |
26 (65.0) |
31 (77.5) |
33 (82.5) |
35 (87.5)* |
|
HDLc disminuido |
33 (82.5) |
31 (77.5) |
33 (82.5) |
35 (87.5)* |
|
LDLc alto |
4 (10.0) |
6 (15.0) |
11 (27.5) |
14 (35.0) |
|
Hipertensión arterial |
13 (32.5) |
6 (15.0) |
13 (32.5) |
17 (42.5) |
|
Obesidad |
24 (60.0) |
23 (57.5) |
23 (57.5) |
22 (56.4) |
|
Síndrome metabólico |
9 (22.5) |
5 (12.5) |
11 (27.5) |
13 (32.5)* |
|
HDLc = colesterol de lipoproteínas de alta densidad. IMC = índice de masa corporal. LDLc = colesterol de lipoproteínas de baja densidad. * p < 0.05. |
||||